|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGMO |
Gene summary for AGMO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGMO | Gene ID | 392636 |
| Gene name | alkylglycerol monooxygenase | |
| Gene Alias | TMEM195 | |
| Cytomap | 7p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q6ZNB7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 392636 | AGMO | NAFLD1 | Human | Liver | NAFLD | 4.03e-15 | 1.34e+00 | -0.04 |
| 392636 | AGMO | S41 | Human | Liver | Cirrhotic | 3.19e-03 | 6.76e-01 | -0.0343 |
| 392636 | AGMO | S43 | Human | Liver | Cirrhotic | 3.82e-07 | -3.02e-01 | -0.0187 |
| 392636 | AGMO | HCC1_Meng | Human | Liver | HCC | 1.56e-118 | 6.60e-02 | 0.0246 |
| 392636 | AGMO | HCC2_Meng | Human | Liver | HCC | 3.20e-16 | -3.58e-01 | 0.0107 |
| 392636 | AGMO | cirrhotic1 | Human | Liver | Cirrhotic | 1.23e-12 | -3.42e-01 | 0.0202 |
| 392636 | AGMO | cirrhotic2 | Human | Liver | Cirrhotic | 3.30e-13 | -3.08e-01 | 0.0201 |
| 392636 | AGMO | cirrhotic3 | Human | Liver | Cirrhotic | 9.79e-03 | -3.70e-01 | 0.0215 |
| 392636 | AGMO | HCC1 | Human | Liver | HCC | 7.27e-06 | 2.15e+00 | 0.5336 |
| 392636 | AGMO | HCC2 | Human | Liver | HCC | 2.10e-08 | 2.36e+00 | 0.5341 |
| 392636 | AGMO | HCC5 | Human | Liver | HCC | 4.27e-06 | 8.84e-01 | 0.4932 |
| 392636 | AGMO | Pt13.a | Human | Liver | HCC | 3.67e-06 | -3.24e-01 | 0.021 |
| 392636 | AGMO | Pt13.b | Human | Liver | HCC | 4.79e-08 | -2.92e-01 | 0.0251 |
| 392636 | AGMO | Pt14.d | Human | Liver | HCC | 2.95e-09 | -3.77e-01 | 0.0143 |
| 392636 | AGMO | S014 | Human | Liver | HCC | 1.42e-10 | 1.04e+00 | 0.2254 |
| 392636 | AGMO | S015 | Human | Liver | HCC | 3.82e-02 | 7.70e-01 | 0.2375 |
| 392636 | AGMO | S016 | Human | Liver | HCC | 3.41e-26 | 1.58e+00 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066413 | Liver | NAFLD | triglyceride metabolic process | 29/1882 | 100/18723 | 9.51e-08 | 7.62e-06 | 29 |
| GO:00066392 | Liver | NAFLD | acylglycerol metabolic process | 32/1882 | 128/18723 | 8.82e-07 | 4.60e-05 | 32 |
| GO:00066382 | Liver | NAFLD | neutral lipid metabolic process | 32/1882 | 129/18723 | 1.06e-06 | 5.35e-05 | 32 |
| GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
| GO:00194322 | Liver | NAFLD | triglyceride biosynthetic process | 13/1882 | 42/18723 | 1.60e-04 | 2.94e-03 | 13 |
| GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
| GO:00464601 | Liver | NAFLD | neutral lipid biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
| GO:00464631 | Liver | NAFLD | acylglycerol biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
| GO:000664111 | Liver | Cirrhotic | triglyceride metabolic process | 40/4634 | 100/18723 | 5.36e-04 | 4.23e-03 | 40 |
| GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:00066412 | Liver | HCC | triglyceride metabolic process | 59/7958 | 100/18723 | 6.35e-04 | 3.93e-03 | 59 |
| GO:000663911 | Liver | HCC | acylglycerol metabolic process | 72/7958 | 128/18723 | 1.16e-03 | 6.54e-03 | 72 |
| GO:000663811 | Liver | HCC | neutral lipid metabolic process | 72/7958 | 129/18723 | 1.54e-03 | 8.14e-03 | 72 |
| GO:00194321 | Liver | HCC | triglyceride biosynthetic process | 26/7958 | 42/18723 | 8.76e-03 | 3.41e-02 | 26 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGMO | SNV | Missense_Mutation | c.961N>G | p.Thr321Ala | p.T321A | Q6ZNB7 | protein_coding | deleterious(0.04) | benign(0.034) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AGMO | SNV | Missense_Mutation | c.25N>C | p.Asp9His | p.D9H | Q6ZNB7 | protein_coding | tolerated(0.05) | benign(0.031) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| AGMO | SNV | Missense_Mutation | c.1128G>C | p.Leu376Phe | p.L376F | Q6ZNB7 | protein_coding | deleterious(0.03) | possibly_damaging(0.542) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGMO | SNV | Missense_Mutation | novel | c.1194N>C | p.Leu398Phe | p.L398F | Q6ZNB7 | protein_coding | tolerated(0.26) | possibly_damaging(0.569) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGMO | SNV | Missense_Mutation | rs756450306 | c.79G>A | p.Glu27Lys | p.E27K | Q6ZNB7 | protein_coding | deleterious(0.03) | possibly_damaging(0.892) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| AGMO | SNV | Missense_Mutation | novel | c.418A>G | p.Ile140Val | p.I140V | Q6ZNB7 | protein_coding | tolerated(0.17) | benign(0.123) | TCGA-ZX-AA5X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| AGMO | SNV | Missense_Mutation | rs769378096 | c.146N>A | p.Ser49Tyr | p.S49Y | Q6ZNB7 | protein_coding | tolerated(1) | benign(0.042) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AGMO | SNV | Missense_Mutation | c.578N>C | p.Asn193Thr | p.N193T | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| AGMO | SNV | Missense_Mutation | novel | c.682A>C | p.Asn228His | p.N228H | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| AGMO | SNV | Missense_Mutation | novel | c.590A>G | p.Gln197Arg | p.Q197R | Q6ZNB7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |